Literature DB >> 26669300

Serum endocan as a survival predictor for patients with liver cirrhosis.

Nobuyuki Toshikuni, Kazuaki Ozaki, Joseph George, Mikihiro Tsutsumi.   

Abstract

BACKGROUND: The relationship between endocan expression and outcome in patients with chronic liver disease is not fully understood.
OBJECTIVE: To examine whether serum endocan level is predictive of outcome in patients with liver cirrhosis.
METHODS: A total of 68 patients with liver cirrhosis were enrolled. Outcome predictors were analyzed using the Cox proportional hazards model. The overall survival rates were calculated using the Kaplan-Meier method, and differences were evaluated using the log-rank test.
RESULTS: During the median follow-up period (7.1 years), nine patients had hepatocellular carcinoma (HCC) and 10 patients died. Of the deceased patients, nine died due to hepatic decompensation or associated conditions. No significant factors were found to be predictive of the occurrence of HCC. In contrast, an elevated serum endocan level (≥2.0 ng⁄mL; HR 2.34 [95% CI 1.05 to 7.03]; P=0.037) and high Child-Pugh grade B⁄C (HR 2.65 [95% CI 1.30 to 6.89; P=0.006) were predictive of poor survival. Kaplan-Meier analysis revealed that the respective cumulative survival rates at five and 10 years were 97.1% and 87.4% in patients with serum endocan levels <2.0 ng⁄mL and 85.8% and 64.4% in patients with levels ≥2.0 ng⁄mL (P=0.009), respectively. Moreover, the cumulative survival rates were significantly different among the patient groups divided according to serum endocan level and Child-Pugh grade (P=0.002).
CONCLUSION: These findings suggest that serum endocan level may be a survival predictor for patients with liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26669300      PMCID: PMC4699609          DOI: 10.1155/2015/153805

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  13 in total

1.  Endocan expression and relationship with survival in human non-small cell lung cancer.

Authors:  Bogdan Dragos Grigoriu; Florence Depontieu; Arnaud Scherpereel; Delphine Gourcerol; Patrick Devos; Taoufik Ouatas; Jean-Jacques Lafitte; Marie-Christine Copin; Andre-Bernard Tonnel; Philippe Lassalle
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

2.  Endocan elicits severe vascular inflammatory responses in vitro and in vivo.

Authors:  Wonhwa Lee; Sae-Kwang Ku; Shin-Woo Kim; Jong-Sup Bae
Journal:  J Cell Physiol       Date:  2014-05       Impact factor: 6.384

3.  Transcriptional repression of the transforming growth factor β (TGF-β) Pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by Nuclear Factor κB (NF-κB) p50 enhances TGF-β signaling in hepatic stellate cells.

Authors:  Cheng Liu; Xiaorong Chen; Ling Yang; Tatiana Kisseleva; David A Brenner; Ekihiro Seki
Journal:  J Biol Chem       Date:  2014-01-21       Impact factor: 5.157

4.  Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer.

Authors:  Na Young Ji; Young-Ho Kim; Ye Jin Jang; Yun Hee Kang; Chung Il Lee; Jae Wha Kim; Young Il Yeom; Ho Kyung Chun; Yoon-Ho Choi; Joo Heon Kim; Jong Wan Kim; Hee Gu Lee; Eun Young Song
Journal:  Cancer Sci       Date:  2010-07-30       Impact factor: 6.716

5.  Ascorbic acid suppresses endotoxemia and NF-κB signaling cascade in alcoholic liver fibrosis in guinea pigs: a mechanistic approach.

Authors:  P A Abhilash; R Harikrishnan; M Indira
Journal:  Toxicol Appl Pharmacol       Date:  2013-11-15       Impact factor: 4.219

6.  Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer.

Authors:  Manal M El Behery; Mahmoud A Seksaka; Moustafa A Ibrahiem; Hend S Saleh; Yehya El Alfy
Journal:  Arch Gynecol Obstet       Date:  2013-05-25       Impact factor: 2.344

7.  Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan.

Authors:  Masatoshi Makuuchi; Norihiro Kokudo; Shigeki Arii; Shunji Futagawa; Shuichi Kaneko; Seiji Kawasaki; Yutaka Matsuyama; Masatoshi Okazaki; Kiwamu Okita; Masao Omata; Yukihisa Saida; Tadatoshi Takayama; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2008-01       Impact factor: 4.288

8.  Endocan expression correlated with poor survival in human hepatocellular carcinoma.

Authors:  Geng-Wen Huang; Yi-Ming Tao; Xiang Ding
Journal:  Dig Dis Sci       Date:  2008-07-01       Impact factor: 3.199

9.  Biological and clinical implications of endocan in gastric cancer.

Authors:  Wenyan Zhao; Ming Sun; Shuqiang Li; Yong Wang; Jingang Liu
Journal:  Tumour Biol       Date:  2014-07-11

10.  Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma.

Authors:  Kazuaki Ozaki; Nobuyuki Toshikuni; Joseph George; Takahiro Minato; Yasuhiro Matsue; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  J Cancer       Date:  2014-03-04       Impact factor: 4.207

View more
  5 in total

1.  ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells.

Authors:  Juan Rebollo; Jan Geliebter; Niradiz Reyes
Journal:  Int J Biomed Sci       Date:  2017-03

2.  Serum endocan levels in patients with stable COPD.

Authors:  Aylin Pihtili; Zuleyha Bingol; Esen Kiyan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-15

Review 3.  Endocan: A Key Player of Cardiovascular Disease.

Authors:  Jinzhi Chen; Liping Jiang; Xiao-Hua Yu; Mi Hu; Yang-Kai Zhang; Xin Liu; Pingping He; Xinping Ouyang
Journal:  Front Cardiovasc Med       Date:  2022-01-05

Review 4.  Endothelial and microvascular function in liver cirrhosis: an old concept that needs re-evaluation?

Authors:  Ioanna Papagiouvanni; Pantelis Sarafidis; Marieta P Theodorakopoulou; Emmanouil Sinakos; Ioannis Goulis
Journal:  Ann Gastroenterol       Date:  2022-07-15

5.  Endothelial Cell-Specific Molecule 1 Promotes Endothelial to Mesenchymal Transition in Renal Fibrosis.

Authors:  Tung-Wei Hung; Chao-Yang Chu; Chen-Lin Yu; Chu-Che Lee; Li-Sung Hsu; Yong-Syuan Chen; Yi-Hsien Hsieh; Jen-Pi Tsai
Journal:  Toxins (Basel)       Date:  2020-08-06       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.